Supernus completes Indivior merger, creating diversified CNS biopharma company
Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026, creating Supernus, Inc. with an 11-product CNS portfolio. Former Indivior stockholders own approximately 56.5% of the combined company and receive a $1 billion special cash dividend, funded partly by a $650 million term loan. The combined company will begin trading on Nasdaq under the Supernus name on November 3, 2026.
Why it matters
The transaction combines the companies under Supernus, changes the ownership structure, and moves Indivior holders into the combined company while providing them with the special dividend. Supernus says the merger expands its commercial scale, cash flow and capacity to pursue pipeline and strategic opportunities.
Key facts
- 1Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026, and the combined company is scheduled to trade under the Supernus name on November 3, 2026. biobuzz.io
- 2Former Indivior stockholders own approximately 56.5% of the combined company on a fully diluted basis. biobuzz.io
- 3The $1 billion dividend to Indivior stockholders is being financed with a $650 million Citibank term loan and existing cash. biobuzz.io
- 4Supernus stockholders received 1.5401 Indivior common shares for each Supernus share they owned. biobuzz.io
- 5The combined company is described as aiming for $125M in annual cost synergies. finance.yahoo.com
Open questions
- The $125M annual cost-synergy figure appears only and is not quantified in the transaction announcement reproduced.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.